Compare · CI vs LH
CI vs LH
Side-by-side comparison of The Cigna Group (CI) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $73.81B, about 2.7x LH ($27.39B).
- LH has been more active in the news (12 items in the past 4 weeks vs 7 for CI).
- Both have 25 recent analyst ratings on file.
- Company
- The Cigna Group
- Labcorp Holdings Inc.
- Price
- -
- -
- Market cap
- $73.81B
- $27.39B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 7
- 12
- Recent ratings
- 25
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest CI
- SEC Form 4 filed by Officer Holgerson Bryan
- Officer Jones Nicole S sold $748,516 worth of shares (2,677 units at $279.61) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 25,880 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- Officer Jones Nicole S exercised 15,346 shares at a strike of $192.02 and sold $5,369,584 worth of shares (19,436 units at $276.27) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 28,557 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- The Cigna Group downgraded by Jefferies with a new price target
- The Cigna Group downgraded by Raymond James with a new price target
- SEC Form 10-Q filed by The Cigna Group
- The Cigna Group filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- The Cigna Group Reports Strong Second Quarter 2026 Results, Raises 2026 Outlook
Latest LH
- Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
- Director Anderson Kerrii B sold $954,060 worth of shares (3,000 units at $318.02) as part of a pre-agreed trading plan, decreasing direct ownership by 31% to 6,563 units (SEC Form 4)
- Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Host Investor Day on September 10, 2026
- Labcorp Holdings Inc. filed SEC Form 8-K: Leadership Update
- President & CEO Schechter Adam H sold $1,495,808 worth of shares (4,669 units at $320.37) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 102,565 units (SEC Form 4)
- Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
- EVP, Chief Marketing Officer Summy Amy B. sold $283,428 worth of shares (924 units at $306.74), decreasing direct ownership by 12% to 6,956 units (SEC Form 4)
- SEC Form 10-Q filed by Labcorp Holdings Inc.